The information is the whole product here. There is no daily protocol to start, no supplement to take, no test to order. What you get from understanding "leaky gut" honestly is a small but real save: you stop spending hundreds on direct-to-consumer panels that detect proteins they aren't supposed to be detecting, you stop committing to six-month elimination diets driven by tests immunologists consider backwards, and you route any real symptoms toward an actual diagnostic workup instead. Read once, recognise the term in the wild, move on.
The gut wall is mostly one cell thick. That's it. A single layer of cells, sealed at their edges by protein clasps called tight junctions, with a mucus layer on top — the real barrier biology the leaky-gut pitch borrows its science from — and an immune layer underneath. Everything you eat ends up pressed against this layer; the tight junctions decide what slips between cells and what doesn't. They're not static gates — they open and close in response to signals, all day long.
One signal opens them more than others. A protein called zonulin is the only known on-switch the body makes for itself Fasano 2012. Gluten triggers it. So do certain gut bacteria. In people genetically primed for celiac disease, the zonulin response is loud enough that gluten fragments slip through, the immune system meets them in the wrong place, and the disease that follows is the textbook example of "leaky" with consequences. In everyone else, the same opening happens at smaller scale, transiently, and the body closes it back up.
Other things bash the barrier more directly. Alcohol metabolites and NSAIDs like ibuprofen damage the cells themselves. Inflammation from Crohn's or ulcerative colitis pulls tight junctions apart with cytokine signals. Running a marathon in 33°C heat shunts blood away from the gut, starves the lining of oxygen, and lets bacterial fragments leak into the bloodstream for the rest of the race Costa et al. 2017. Giving a public speech does the same thing for an hour, through a stress-hormone pathway Vanuytsel et al. 2014. None of this is mystical — it's measured, repeatable, mechanistically clear.
What's contested isn't the mechanism. It's the leap from "this happens" to "this is the hidden cause of your problems."
Where the evidence is real, and where it stops
Inside named diseases, the evidence is solid. Celiac patients have measurably leaky guts when they're eating gluten; ~87% normalise within a year of strict gluten-free eating. About half of Crohn's patients show elevated permeability between flares, and the change can predict the next flare months out. A 2021 systematic review of 66 IBS studies found measurable permeability changes in 37–62% of people with diarrhoea-predominant IBS, and 16–50% of those whose IBS started after a stomach bug Hanning et al. 2021. Fatty liver disease, type 1 diabetes, severe burns, and ICU sepsis all show it too.
Outside named diseases, the picture thins fast. The cleanest test anyone has run on the "fix the permeability, fix the disease" idea was a drug called larazotide acetate — a synthetic peptide that blocks the zonulin pathway. In a 342-person Phase 2b trial it cut symptom days by about 26% in celiac patients still feeling sick on a gluten-free diet Leffler et al. 2015. The follow-up Phase 3 trial — the first ever Phase 3 trial for any celiac drug, with FDA fast-track designation — was discontinued in June 2022 after an interim look showed the gap from placebo wasn't going to be big enough to matter 9 Meters 2022. The cleanest possible test of the premise, in the population with the strongest mechanistic case, did not deliver.
For supplements, the pooled evidence is modest. A 2025 meta-analysis of 24 probiotic and synbiotic trials found real reductions in circulating bacterial endotoxin, but rated the certainty of evidence as "very low" to "moderate" — the trials are heterogeneous and individually small Pires Picoli et al. 2025. A 2024 meta-analysis of glutamine — the supplement most often sold as a gut-lining repair fuel — found no significant effect on permeability overall. A signal showed up only at more than 30 grams a day for under two weeks, in burns patients and post-infectious IBS Ghaffarzad et al. 2024. That's six teaspoons a day, short-term, for specific clinical situations — not what's marketed.
For the idea that a leaky gut in an otherwise-healthy person is the hidden cause of their fatigue, brain fog, joint pain, eczema, anxiety or weight: there is no strong evidence. Cross-sectional links keep showing up — depression, schizophrenia, chronic fatigue all show elevated permeability markers on average — but no one has yet shown that the permeability came first, or that fixing it changes the outcome Lacy et al. 2024.
The tests sold for it don't measure what they claim
The most popular at-home and clinic-ordered "leaky gut" test measures a protein called zonulin in your blood or stool. There is a problem: independent labs have shown that the most widely-used commercial zonulin kits don't detect zonulin. They detect other proteins — complement C3 fragments and a protein called properdin — that the original antibodies were never meant to find Scheffler et al. 2018 Ajamian et al. 2019. A "high zonulin" result from a panel you ordered online is a high reading of something. Nobody knows exactly what.
The other common test, an IgG food sensitivity panel, has a different problem. It measures how much IgG antibody your blood carries against foods you eat. Allergy doctors and immunologists across multiple national societies have said for years that IgG against food is a marker of tolerance, not damage — it goes up because you've eaten the food regularly and your immune system has learned to ignore it. Reading high IgG as evidence of a "leaky gut letting food protein into your blood" runs the immunology backwards. The eliminations the panels prescribe — pull these twenty foods for three months — are based on what is essentially a list of foods you eat often.
And the syndrome itself, separately from the tests: "leaky gut syndrome" is not in any diagnostic manual. It has no medical code. Mayo Clinic and Cleveland Clinic both state plainly that it isn't a recognised diagnosis. The American Gastroenterological Association and the British Society of Gastroenterology have published guidance on every condition that does involve a leakier-than-normal gut, and none of them treat "leaky gut" as a standalone disease BSG 2021. A gastroenterologist who tells you that you have leaky gut syndrome is, as one of them put it, telling you "you've got a diagnosis that still needs to be made."
What testing actually looks like
The closest thing to a gold-standard permeability test, used since the 1970s, is the lactulose:mannitol ratio. You drink two sugars: one (mannitol) crosses the gut wall through the cells, the other (lactulose) crosses between them. They both end up in your urine. The ratio between the two over a few hours tells you how leaky the gaps between cells are. It works. It's used in research. It is not what's being sold online, and it isn't ordered routinely by clinicians either — labs do it differently enough that comparing results between centres is hard, and there's no recognised disease called "leaky gut" to treat with the answer Camilleri 2019.
Hospitals have other research-grade tools: confocal microscopy through a colonoscope that watches the gut wall react to food in real time, blood markers like I-FABP for damaged gut cells, blood markers like LBP for bacterial endotoxin in circulation. None of these is a "leaky gut" diagnostic in the sense the marketing implies, either. They're tools for understanding disease, not for stamping a label on someone.
What you can get over the counter is roughly:
- Zonulin panels, blood or stool, $100–$400. The kit doesn't measure zonulin.
- IgG food sensitivity panels, $200–$400. Measures tolerance, sold as pathology.
- Comprehensive "gut health" stool tests, $300–$500. Bundle the above with microbiome readings; no result connects reliably to any treatment.
If you have real digestive symptoms — recurring diarrhoea, bloating that won't quit, unexplained weight loss, blood in stool, iron deficiency that keeps coming back — the diagnostic workup that finds what's wrong is the standard one: a doctor's visit, blood work that includes celiac antibodies and total IgA, stool calprotectin for inflammation, and a colonoscopy if anything looks alarming. The BSG IBS guideline lays out the standard sequence BSG 2021. None of this is exotic, none of it requires a functional-medicine clinic, and most of it is covered by insurance or your national system.
What to actually do
The whole entry's action is informational. There is no daily protocol. What there is, is a short checklist for handling the term when you meet it.
For supplements that get bundled with the marketing: glutamine shows a real signal at very high doses, short-term, in specific clinical situations (burns, post-infectious IBS) Ghaffarzad et al. 2024. Outside those situations, the meta-analysis comes out flat. Probiotics and synbiotics reduce bacterial endotoxin in your blood across pooled trials, but the certainty of the evidence is low and the long-term clinical meaning is unclear Pires Picoli et al. 2025. None of these is a cure for a non-disease; treat them as ordinary tools, not a protocol.
How people get this wrong in practice
The common failure isn't believing in leaky gut. The common failure is finding a label that explains everything — and stopping there. Someone is tired, bloated, fogged up, breaking out, and the "leaky gut" frame ties the whole list together. Months later they've spent a few thousand dollars on tests and supplements, cut twenty foods, and the real thing — undiagnosed celiac in about 1% of cases, an IBD flare, bile-acid malabsorption, a low-FODMAP responder, sometimes just chronic alcohol exposure — is still there.
The other common failure is the supplement stack. Each individual product is plausible (glutamine fuels gut cells, zinc supports the lining, probiotics shift the microbiome) and each is sold at a dose and price you wouldn't buy for any single one of those reasons on its own. Stacked together for "leaky gut protocol" the bill runs $100–$200 a month and the evidence for any clinical endpoint outside the named diseases is thin Lacy et al. 2024.
And the elimination-diet failure: someone runs an IgG panel, eliminates the twenty foods that came back "high," feels better for two weeks (the placebo effect on chronic GI symptoms is huge — roughly a third of people respond to sugar pills), reintroduces foods slowly, and ends up with a list of "sensitivities" that's actually a list of foods they happen to eat regularly. Re-run the same panel six months later and the list changes, because the panel tracks recent exposure, not pathology.
Where the actual harm lives
The intestinal-permeability biology, as a phenomenon happening in your body right now, isn't going to hurt you. The risk is downstream — in what gets done about it.
What's at stake if you stay inside the marketed version
Picture the version of someone who keeps chasing the syndrome. Six months in, they've got a kitchen cupboard full of beige powders and a fridge organised around what's "allowed this week." Dinner with friends is an annotation exercise. Their partner has stopped asking what's for dinner because the answer is always a variation of the same restrictive plate. They've spent the price of a decent holiday on tests and supplements that produce no answer anyone can act on, and the original symptoms — the bloating, the afternoon crashes, the patchy sleep — are right where they were in January.
A year in, the picture deepens. Friends have learned not to suggest a new restaurant. The reading habit has narrowed to wellness podcasts and the same five Instagram accounts that keep recommending the next supplement. Twenty pounds and a thousand dollars later, the version of them that was looking for an explanation is still looking, and the version of them that could have spent a Tuesday afternoon getting a celiac antibody draw and a stool calprotectin has not.
The worst version of the story is the one where the real diagnosis was sitting there the whole time. Celiac disease affects about 1% of the population and most cases are still undiagnosed; untreated, it climbs the long-run risk of an aggressive lymphoma over decades. Inflammatory bowel disease has its own untreated trajectory ending in surgery for a meaningful fraction of patients. A leaky-gut diagnosis isn't wrong because the gut isn't leaky. It's wrong because it stops the search.
What changes when you take the right half seriously
The week after you read this, the shift is small and internal. You don't buy the test that came up in an ad. You don't add the $40 jar of glutamine to your cart. You scroll past the podcast episode promising to "heal your gut in 30 days" with less reluctance than you thought you'd have.
The month after, the shift gets practical. If your symptoms were real, you've made a regular GP appointment instead of a functional-medicine one. Bloods come back. Either something shows up — celiac antibodies positive, iron low, calprotectin elevated, a real diagnosis with a real protocol behind it — or they don't, and the search continues somewhere honest. People around you stop hearing the long list of foods you can't eat. Dinner with friends is dinner with friends.
The year after, the change is mostly absence. You haven't been carrying the low-grade weight of "I might have an undiagnosed hidden condition causing everything." If you actually had celiac, you've been on a gluten-free diet for ten months and your gut wall has by now returned to normal permeability — measurably, not metaphorically Fasano 2012. If you had IBS-D, you've worked through low-FODMAP under a dietitian's eye and know what your real triggers are. If you had nothing, the symptoms got handled the boring way — sleep, alcohol, NSAID use, stress, regular meals — and the next time a friend forwards you a leaky-gut TikTok you'll be able to say, in one sentence, what it is and isn't.
Related entries
The conditions that actually drive measurable intestinal permeability each have their own entry. If anything in this one rang a bell, the more useful read is probably one of these:
- Celiac disease — the textbook leaky-gut condition, the one with a real test, a real treatment, and a real cost to missing it.
- Inflammatory bowel disease — Crohn's and ulcerative colitis; permeability is part of the picture, but it's the inflammation that needs treating.
- Irritable bowel syndrome — particularly the diarrhoea-predominant and post-infectious subtypes, where the permeability data is real and the treatment is well-defined.
- Food sensitivity testing — the longer version of why IgG panels read the immunology backwards.
- The gut microbiome — what's actually known versus what's marketed about the bacteria living downstream of all this.
- Chronic alcohol use and chronic NSAID use — the two everyday exposures that genuinely damage the gut barrier over years.
- — Chronic drinking is one of the documented, measurable causes of a genuinely leaky intestinal lining — the real half of this story, not the marketed one.
- — A leaky barrier often tracks with too little butyrate. Feeding the bacteria that make short-chain fatty acids helps reseal it.
- — The mucus layer is the actual barrier biology behind real intestinal permeability — the science 'leaky gut syndrome' borrows from.
- — Crohn's and colitis are conditions where the gut wall really is more permeable — if you have real red-flag symptoms, get the workup.
- — A 'leaky gut' label often launches a months-long elimination diet you didn't need — know that before you start cutting foods.
- — Brain fog and mood are sold as 'leaky gut' symptoms; the real gut-mood wiring is the gut-brain axis, not a permeable intestine.
- — Both get sold as the hidden cause of vague symptoms; the IgG test is the panel 'leaky gut' clinics love to order.
- — Lectin-free diet books sell raw lectins as a top cause of a leaky gut. Cooking handles the real risk; the rest is the same marketing.
- — Fatty liver is one condition where the gut lining genuinely does get leakier — it's on the real side of this, not the marketed one.
- — Both are real-sounding labels marketed well beyond the evidence; people often get told they have both at once.
- — Like the colonic 'detox' pitch, leaky gut mixes real biology with oversold marketing — know which half.
1. Substance and claimed effects
"Leaky gut" is two distinct objects sharing one name. The first is intestinal hyperpermeability — a measurable physiological state in which the single-cell intestinal epithelium and its tight-junction protein complexes allow increased paracellular passage of luminal contents (small probe sugars in vivo; bacterial lipopolysaccharide and macromolecules in pathology). It is a documented feature of celiac disease, inflammatory bowel disease (Crohn's and ulcerative colitis), non-alcoholic fatty liver disease, IBS-D and post-infectious IBS, chronic NSAID and alcohol exposure, severe burns and critical illness, strenuous endurance exercise (especially under heat stress), and acute psychological stress Camilleri 2019 Odenwald & Turner 2013 Hanning et al. 2021 Costa et al. 2017 Vanuytsel et al. 2014.
The second object is "leaky gut syndrome" — a commercial syndrome construct popularised in functional and integrative medicine, in which generalised tight-junction loosening is asserted to be the hidden cause of food sensitivities (via IgG responses to translocated food peptides), systemic low-grade inflammation, autoimmune disease, eczema, fatigue, brain fog, anxiety, depression, weight gain, and a broader miscellany of chronic symptoms. The syndrome is not a recognised diagnosis in the AGA, BSG, NICE, or Mayo Clinic frameworks Lacy et al. 2024. It is, however, the object around which a substantial supplement, direct-to-consumer testing, and elimination-diet industry has grown.
This entry covers both, because the reader will encounter both: the real intestinal-permeability phenomenon and the marketed catch-all. Scope: the underlying biology, the evidence for and against the syndrome framing, the diagnostic tests (validated and commercial), the marketed treatments and their evidence base, and the practical question of what the reader should do.
2. Evidence by addressing question
Mechanism
The intestinal barrier is a layered system: an outer mucus layer with secretory IgA and antimicrobial peptides, a single-cell epithelium sealed by intercellular tight junctions, and a sub-epithelial immune compartment (lamina propria with macrophages, dendritic cells, Peyer's patches) Camilleri 2019. Tight junctions are protein complexes — claudins (a family of 27+), occludin, junctional adhesion molecules, and the scaffolding ZO-1/ZO-2/ZO-3 — that seal the paracellular space between epithelial cells Odenwald & Turner 2013. They are not static gates: they regulate dynamic, size-selective paracellular flux through two functionally distinct pathways (the high-capacity, charge- and size-selective "pore" pathway via claudin pores, and the low-capacity "leak" pathway responsive to cytoskeletal contraction and inflammatory cytokines).
The only known endogenous physiological modulator of human tight-junction permeability is zonulin, identified by Fasano as pre-haptoglobin 2 (preHP2) Fasano 2012. Zonulin signalling is triggered by gliadin (the disease-relevant fragment of wheat gluten) and certain enteric bacterial exposures; it transiently disassembles tight junctions through PAR2/EGFR-mediated cytoskeletal contraction. In genetically susceptible individuals — HLA-DQ2/DQ8 in celiac, plus the HP2-2 haplotype — repeated zonulin-driven opening allows gliadin peptides to reach lamina propria immune cells, triggering the autoimmune cascade. The pathway is sufficiently well-characterised to have generated a drug candidate, larazotide acetate (a zonulin antagonist) Leffler et al. 2015.
Other mechanisms of barrier compromise: pro-inflammatory cytokines (TNF-α, IFN-γ, IL-13) drive myosin light-chain kinase-mediated contraction and reorganisation of tight-junction proteins; epithelial apoptosis exposes leak channels; bile acids, ethanol metabolites and NSAIDs directly disrupt the lipid bilayer of enterocytes Odenwald & Turner 2013. The systemic-effect arm of the theory — that increased permeability lets luminal lipopolysaccharide cross into the portal circulation and drive low-grade TLR4-mediated inflammation ("metabolic endotoxaemia") — has mechanistic support in murine models and circumstantial support in human obesity, NAFLD and exercise studies Costa et al. 2017, though the causal direction in chronic human disease remains contested.
Evidence
Defined diseases where intestinal hyperpermeability is documented. The strongest evidence is in celiac disease: active disease shows markedly elevated lactulose:mannitol ratios, zonulin upregulation, and tight-junction disorganisation, all of which normalise in ~87% of patients after ≥12 months on a strict gluten-free diet Fasano 2012. In Crohn's disease, increased small-bowel permeability is a robust finding and can precede clinical relapse by months. In IBS, a 2021 systematic review of 66 studies found 37–62% of IBS-D and 16–50% of post-infectious IBS patients had measurable elevations in permeability versus healthy controls, with substantially lower rates (4–25%) in IBS-C Hanning et al. 2021. Permeability changes correlated with abdominal pain severity. NAFLD/MASLD, type 1 diabetes, environmental enteropathy and HIV enteropathy all show measurable barrier dysfunction; in each case the dominant view is that permeability is a consequence (or amplifier) rather than the root cause.
Acute physiological provocations. Strenuous endurance exercise — especially in heat — reliably elevates intestinal permeability and circulating endotoxin. A systematic review found marathon and ≥70% VO2max running with core temperature ≥39°C produced the highest permeability spikes; 81% of runners requiring medical care after an 89.4 km ultramarathon were endotoxaemic Costa et al. 2017. NSAIDs, alcohol (acute and chronic), radiation, chemotherapy and severe burns all directly degrade barrier function. Acute psychological stress is sufficient: in healthy volunteers, a public-speaking task elevated lactulose:mannitol ratio in proportion to cortisol elevation, an effect blocked by mast-cell stabilisation and reproduced by exogenous CRH Vanuytsel et al. 2014.
The pharmacological test case. Larazotide acetate, a synthetic 8-amino-acid peptide zonulin antagonist, was the most direct test of the "modulate permeability to treat downstream disease" hypothesis. In a 342-patient Phase 2b trial (Leffler et al. 2015) in celiac patients with persistent symptoms despite a gluten-free diet, the 0.5 mg dose reduced symptom days by ~26% versus placebo Leffler et al. 2015. The Phase 3 CeDLara trial (the first ever Phase 3 trial for a celiac disease drug, FDA Fast Track designation) was discontinued in June 2022 after an interim analysis showed the separation from placebo was too small to be reachable within feasible sample size 9 Meters 2022. This is the central skeptic-side data point: the cleanest possible test of the leaky-gut therapeutic premise, in the population with the strongest mechanistic rationale, did not deliver clinical benefit.
Marketed treatments. A 2025 meta-analysis of 24 trials (n=1603) found probiotic, prebiotic and synbiotic supplementation produced statistically significant reductions in circulating LPS and (in some analyses) zonulin, but with high heterogeneity and "very low" to "moderate" GRADE certainty of evidence Pires Picoli et al. 2025. A 2024 meta-analysis of glutamine supplementation showed no significant effect on intestinal permeability overall; a significant reduction emerged only at doses >30 g/day for <2 weeks, in specific clinical populations (post-infectious IBS-D, burns) Ghaffarzad et al. 2024. Zinc carnosine has small-trial support for NSAID-induced permeability protection. None of these is a validated treatment for the marketed syndrome.
Evidence for "leaky gut syndrome" as the cause of generalised chronic illness in otherwise-healthy people. Absent. Associations between permeability biomarkers and depression, schizophrenia and chronic fatigue are real and being studied (multiple recent systematic reviews) but cross-sectional and unable to establish causation; the field is at the "interesting signal" stage, not the "treat permeability to cure depression" stage Lacy et al. 2024.
Misconceptions
Commercial zonulin assays do not measure zonulin. The most widely-deployed commercial ELISA kits (Immundiagnostik, CUSABIO) were validated against an early protein sequence that has since been shown not to correspond to actual pre-haptoglobin 2. Mass spectrometry analyses by Scheffler et al. 2018 and Ajamian et al. 2019 demonstrated that these assays are detecting complement C3 fragments, properdin and other zonulin-family analog proteins — not zonulin itself Scheffler et al. 2018 Ajamian et al. 2019. A "high zonulin" reading from a direct-to-consumer panel is therefore an uninterpretable signal of an unknown protein. The same critique applies to most published research that used these kits.
IgG food sensitivity tests are not leaky-gut tests. Marketed IgG panels (Genova, Everlywell, etc.) measure circulating IgG against food antigens and frame elevations as evidence of leaky gut driving immune reactivity. Allergy/immunology consensus is the opposite: food-specific IgG (particularly IgG4) is a marker of immune tolerance, not pathology — it reflects ongoing exposure and modulation, not damage. The Canadian Society of Allergy and Clinical Immunology, the AAAAI, and EAACI have all issued statements against their clinical use. Elimination diets driven by these panels routinely produce false restrictions.
"Leaky gut syndrome" is not in any diagnostic manual. It has no ICD-10 code. Cleveland Clinic and Mayo Clinic public-facing materials state the syndrome is not a recognised diagnosis; mainstream gastroenterology treats increased permeability as a feature of identifiable underlying disease, not a standalone disease Lacy et al. 2024. The BSG IBS guidelines do not endorse "leaky gut" testing or treatment BSG 2021.
Animal-model translation is fraught. Pre-haptoglobin 2 (zonulin) is uniquely human — mice express only HP1. Murine "zonulin" measurements in the leaky-gut literature are therefore detecting unrelated proteins, complicating mechanistic claims that bridge from mouse models to human disease.
Practicalities
The research-grade test for small-intestinal permeability is the dual-sugar (lactulose:mannitol) test: oral administration of two sugars that traverse the epithelium by different routes (mannitol transcellularly, lactulose paracellularly through tight junctions), followed by timed urinary collection (typically 2–5 hours) and ratio calculation. Used since the 1970s; remains the closest thing to a gold standard, but suffers known limitations — variability between labs, gastric-emptying and renal-function confounding, no standardised collection window, region-specific (assesses small intestine; expanded protocols with sucrose and sucralose add gastric and colonic assessment) Camilleri 2019. It is research-grade, not routine clinical care, and no test reliably identifies "leaky gut syndrome" as a discrete disease.
Other measurement modalities: confocal laser endomicroscopy during colonoscopy (visualises real-time tight-junction leakiness in response to food challenges); serum/plasma intestinal fatty-acid binding protein (I-FABP, marker of enterocyte injury); circulating LPS and LPS-binding protein (endotoxin translocation); biopsy-based Ussing chamber permeability measurements (invasive, research-only). None is deployed for routine "leaky gut" diagnosis.
Direct-to-consumer testing market: zonulin serum or stool panels ($100–400), IgG food sensitivity panels ($200–400), comprehensive "gut health" stool tests bundling many of the above. None has clinical validation to predict disease, response to treatment, or any actionable outcome Lacy et al. 2024.
Protocol
For the recognised causes of intestinal hyperpermeability, treatment is treatment of the underlying disease: gluten-free diet for celiac (restores barrier in ~87% within a year), induction and maintenance therapy for IBD, alcohol cessation, NSAID avoidance or PPI co-therapy, treating SIBO if present, addressing chronic stress. Permeability is a downstream marker; the upstream condition is what to treat.
For the reader presenting with symptoms commonly attributed to "leaky gut" — chronic fatigue, bloating, brain fog, joint pain, eczema flares — the protocol is to see a gastroenterologist and rule out the conditions that actually do drive permeability: celiac (tTG-IgA plus total IgA, or endoscopy), IBD (calprotectin, colonoscopy), IBS subtype (Rome criteria), SIBO (breath testing), bile-acid malabsorption, dietary triggers (low-FODMAP trial under dietitian supervision). The BSG IBS guidelines provide the standard diagnostic approach BSG 2021.
Supportive measures with reasonable evidence: fibre intake (prebiotic substrate; bolsters short-chain fatty acid production which supports barrier integrity), fermented foods (modest microbiome effects), omega-3 (anti-inflammatory; weak permeability data), reducing chronic alcohol and NSAID exposure, stress regulation. None is a "cure for leaky gut" but each is a defensible component of GI health.
Specific supplements with the most evidence: glutamine at doses ≥30 g/day for ≤2 weeks shows permeability reduction in burns and post-infectious IBS-D — population-specific, short-term, and the overall meta-analysis is null Ghaffarzad et al. 2024. Probiotics/synbiotics reduce LPS markers across heterogeneous trials with very low to moderate certainty Pires Picoli et al. 2025. Zinc carnosine has small-trial support for NSAID-induced damage. None is a validated treatment for a non-disease.
Contraindications
The main reader-side risks are not from intestinal permeability itself but from the marketed treatment pathway: aggressive elimination diets (commonly removing gluten, dairy, soy, eggs, nightshades, corn, sugar, alcohol, "all processed food" for 3–6 months) driven by IgG panels carry real risk of nutritional inadequacy, social-eating impairment, and disordered-eating onset or relapse, especially in adolescents, young women, and patients with prior ED history. There is no high-quality evidence that 3–6-month restriction "heals leaky gut" in otherwise-healthy people. Stacked high-dose supplementation (glutamine, zinc, "gut repair" formulas) costs hundreds per month with weak or absent evidence for non-clinical populations. Most consequential: chasing the syndrome diverts attention from real underlying diagnoses — undiagnosed celiac, IBD, colorectal pathology in older adults, or a treatable IBS subtype.
Stakes
For the reader chasing the syndrome construct: months to years of restrictive eating, several thousand dollars in tests and supplements, anxiety-amplifying "high zonulin" results that don't measure zonulin, and a real underlying condition (sometimes celiac, sometimes IBD, sometimes just IBS) that goes properly investigated only later. For someone with an actual underlying disease driving permeability (untreated celiac, active Crohn's, chronic heavy alcohol use, NSAID polypharmacy): the long-term stakes are those of the disease — for celiac, enteropathy-associated lymphoma and refractory celiac at decades-long timescales; for IBD, surgical risk; for chronic alcohol, cirrhosis. Those stakes belong to the underlying-condition entries, not this one.
Payoff
The informational payoff of getting "leaky gut" right is asymmetric. A reader who understands the distinction stops paying for invalid tests, stops following restrictive protocols that don't deliver, and routes themselves to the diagnostic workup that will actually find a treatable condition if one exists. For readers whose real underlying issue gets identified and treated — celiac on a GFD, IBD on therapy, alcohol cessation — barrier function normalises measurably within months to a year, symptoms attributed to "leaky gut" often resolve, and the marketed-syndrome chase ends.
Out of scope
This entry does not duplicate condition-specific entries. Celiac disease, inflammatory bowel disease, IBS subtypes, NAFLD, SIBO, chronic alcohol exposure, chronic NSAID use, the gut microbiome, and IgG food sensitivity testing each warrant their own entries (or already have them) and are covered in the article's closing pointers, not enumerated here.
3. The credibility range
The optimist case
Intestinal hyperpermeability is real, mechanistically defined, and measurable. The zonulin/tight-junction pathway is the only known endogenous regulator of paracellular permeability and is sufficient to drive clinically meaningful disease in celiac. Permeability changes are documented across an expanding set of conditions — IBD, IBS-D, post-infectious IBS, NAFLD, type 1 diabetes, depression, schizophrenia — and in several cases (Crohn's, celiac first-degree relatives) precede clinical disease, suggesting causal rather than purely consequential involvement. Bacterial endotoxin translocation across a compromised barrier is a plausible driver of low-grade systemic inflammation, with circumstantial human support in metabolic disease and exercise studies. Probiotic and synbiotic interventions show signal across pooled trials. The functional-medicine community may have identified a real phenomenon ahead of formal clinical validation, much as the obesity–inflammation link was dismissed before it became orthodoxy. Pharmacological targeting of the pathway remains an active research direction post-larazotide.
The skeptic case
"Leaky gut syndrome" as a discrete, treatable condition causing chronic illness in otherwise-healthy people is not recognised by any major medical society, has no validated diagnostic test, and has no treatment with high-quality randomised evidence in non-diseased populations. The cleanest pharmacological test of the premise — larazotide acetate in symptomatic celiac, a population with the strongest mechanistic case — failed in Phase 3 in 2022, with the trial discontinued for insufficient separation from placebo. The most widely-deployed commercial test, serum or stool zonulin, does not measure zonulin: independent mass-spectrometry work has shown the commercial ELISAs detect complement C3 fragments and properdin instead. IgG food sensitivity panels misinterpret a tolerance marker as a pathology marker. The lactulose:mannitol test is research-grade and varies enough between labs that clinical deployment is unreliable. Most permeability changes documented in disease appear to be consequences of inflammation, not causes; treating the underlying inflammation restores barrier function without targeting permeability directly. The commercial ecosystem (tests, supplements, elimination-diet courses) substantially outruns the evidence and produces real harm: delayed diagnosis, restrictive eating, financial waste, anxiety amplification.
The author's call
Both positions are partly right and the entry must hold them simultaneously. The biology is real and clinically meaningful within recognised diseases — celiac, IBD, post-infectious IBS, NAFLD, severe burns, intense exercise under heat — where measurement and (in some cases) targeted treatment may have a role. The marketed syndrome is a commercial overreach: not a diagnosis, not testable with the panels sold, not treatable with the protocols sold. The reader's action is informational, not interventional. Recognise the term for what it is in the wild, route any real symptoms through a proper diagnostic workup, do not pay for zonulin or IgG panels, and be skeptical of "heal your gut" courses sold as cures. evidence: 3 overall (well-evidenced biology, weak-to-absent evidence for the marketed syndrome); controversy: 4 (active and live disagreement between mainstream gastroenterology and functional-medicine practitioners, with both sides citing real data).
4. Stakeholder and incentive map
- Commercial pro-side. Supplement manufacturers (L-glutamine, zinc carnosine, "gut repair" formula brands; estimated multi-billion-dollar market segment within the broader supplement industry). Direct-to-consumer testing labs (Genova Diagnostics, Everlywell, Vibrant Wellness — zonulin panels, IgG food sensitivity panels, comprehensive stool tests). Functional and integrative medicine practitioners (consulting fees, course sales, branded protocols). Wellness influencers and bestselling-book authors who built audiences on "the hidden cause" framing.
- Cautious mainstream. American Gastroenterological Association, British Society of Gastroenterology, Mayo Clinic, Cleveland Clinic, NICE. Position: increased permeability is real and clinically interesting within defined diseases; "leaky gut syndrome" is not a diagnosis and commercial tests are unreliable Lacy et al. 2024.
- Active research. Alessio Fasano (Mass General; zonulin discovery; commercial interest as Alba Therapeutics shareholder, disclosed). Michael Camilleri (Mayo Clinic; clinical permeability measurement). Jerrold Turner (Brigham & Women's; paracellular biology). The pharmaceutical interest peaked with 9 Meters Biopharma's larazotide programme and has cooled since the Phase 3 failure.
- Counter-incentive. Allergy/immunology societies (CSACI, AAAAI, EAACI) — formal positions against IgG food testing. Skeptic publications (Science-Based Medicine, Examine.com summaries) — public-facing critiques of the syndrome construct.
5. Population variability
- Established gut disease. Celiac (HLA-DQ2/DQ8 carriers especially), Crohn's, ulcerative colitis, IBS-D and post-infectious IBS — permeability changes documented and clinically relevant. Treat the underlying disease.
- First-degree relatives of celiac patients. Asymptomatic, seronegative FDRs show structural tight-junction changes in research biopsies, plus elevated rates of seroreactivity to bacterial markers — suggests permeability shifts may precede clinical disease in genetic susceptibles. Of clinical interest but not a screening indication.
- Endurance athletes. Marathon, ultramarathon, Ironman, hot-condition training — transient exercise- and heat-induced permeability with quantitatively elevated post-event LPS. Recovery within hours to days Costa et al. 2017. Practical implications are mostly performance and GI-symptom focused.
- Critical care, burns, sepsis, major surgery. Significant permeability disruption; this is where high-dose enteral glutamine has the strongest barrier-function evidence (though clinical-endpoint trials in ICU populations have been mixed).
- Chronic alcohol use and chronic NSAID use. Direct barrier compromise; cessation/reduction is the intervention.
- Healthy adults with non-specific symptoms. The population most exposed to the marketed-syndrome ecosystem; the population with the least evidence that permeability is driving anything actionable.
- Pregnancy. Restrictive elimination diets carry nutritional risk; supplements with weak evidence are inadvisable.
- Adolescents and patients with eating-disorder history. Elimination-diet protocols carry meaningful risk of disordered-eating onset or relapse.
6. Knowledge gaps
No validated, routine, clinically-actionable test for intestinal permeability exists. The lactulose:mannitol ratio remains research-grade with cross-lab variability. Whether permeability changes are causal or consequential is unresolved for many associations (depression, schizophrenia, NAFLD progression, autoimmune disease onset). Whether pharmacologically or nutritionally reducing permeability changes hard clinical endpoints in non-diseased populations is unknown — the one large pharmacological test (larazotide Phase 3) failed even in celiac. Long-term safety and efficacy of high-dose glutamine outside critical care is uncharacterised. The microbial-dysbiosis arm of the picture — which strains, which prebiotic substrates, which patient subgroups — remains pre-paradigmatic. A reliable, commercially-available zonulin assay does not exist; the field needs a new monoclonal-based assay validated against actual preHP2.
Evidence that would change the author's call: a positive Phase 3 trial of a tight-junction-targeted drug in a non-celiac population (would move evidence from 3 to 4); a validated DTC test with prospective predictive validity for clinical endpoints (would move controversy down); a large prospective cohort showing that elevated permeability in healthy adults independently predicts subsequent diagnosis of named diseases (would partially rescue the "leaky gut as cause" framing).
Scope call. The brief named five consequences (systemic inflammation claims, food sensitivity attribution, autoimmune theories, diagnostic clarity, treatment marketing). All five are covered, though the article folds them into a tighter structural frame: the biology section covers mechanism (relevant to autoimmune theories and systemic inflammation claims), evidence handles the autoimmune and inflammation claims directly, misconceptions covers food sensitivity attribution and diagnostic clarity, practicalities covers diagnostic clarity from the test side, and protocol + failure-modes + contraindications cover treatment marketing.
Action type call. Picked know rather than avoid. The reader's task is informational — recognise the term, distinguish real biology from marketed syndrome, route real symptoms through a proper workup. There's no daily behaviour to do or avoid. The closest argument for avoid would be "don't pay for the panels," but that's a single one-time call inside a broader information frame, and know better matches the entry's centre of gravity.
Cadence is once. Read once, understand the distinction, move on. The biology will not change fast enough to warrant rereading; if the larazotide successor programme produces something, the entry gets a small update.
Why scores are low across benefit dimensions. Informational entries about contested syndromes should not inflate benefit dimensions because "understanding is good." The actual reader-side win is small in magnitude: a modest health_short_term for avoiding restrictive diets and unvalidated supplements, a modest mood for not carrying low-grade health-anxiety. Everything else is zero. The real benefits (catching celiac, treating IBD, reducing alcohol, stopping chronic NSAIDs) belong to the entries on those conditions; scoring them here would double-count and inflate this entry artificially.
Why evidence: 3 rather than higher. Mixed by design. The underlying biology is well-evidenced — multiple landmark reviews (Camilleri 2019 Gut, Odenwald & Turner 2013 CGH, Fasano 2012 CGH) plus a 2021 IBS systematic review and a 2017 exercise-induced GI syndrome systematic review. The marketed syndrome side has weak-to-absent evidence and a flagship drug failure. A single score cannot capture both; 3 is the honest midpoint and the article body articulates the split rather than trying to average it.
Why controversy: 4. Foundational disagreement between mainstream gastroenterology (AGA, BSG, NICE, Mayo, Cleveland — leaky gut syndrome is not a diagnosis) and functional/integrative medicine (treats it as a primary cause). Both sides cite real data. A multi-billion-dollar test and supplement market sits on the contested side. Not 5 because the underlying biology isn't contested — the disagreement is about what the biology means, not whether it exists.
What was excluded. The depression/schizophrenia leaky-gut-biomarker literature is genuinely interesting but at the "interesting correlation" stage; including it in the article body would push the reader toward conclusions the evidence does not yet support. Mentioned briefly in evidence; covered in the research dossier. The history addressing key was considered (Fasano's zonulin discovery story, the rise of functional medicine as a movement, the supplement industry's 2010s pivot to gut health) but the article reads tighter without it.
Separate-entry candidates flagged for the backlog.
- IgG food sensitivity testing — referenced here but deserves a focused entry on the immunology and the test-marketing landscape.
- Direct-to-consumer health testing as a category — zonulin panels, IgG panels, comprehensive stool tests, microbiome kits all share the same diagnostic-marketing pattern; a category entry would be useful.
- Functional medicine as a medical movement — beyond scope here but recurs across the catalogue.
Future links to wire when entries exist. Celiac disease, IBD (or Crohn's / UC separately), IBS, food sensitivity testing, gut microbiome, chronic alcohol use, chronic NSAID use, low-FODMAP diet, SIBO, NAFLD/MASLD. The related meta field currently points at the first five.
Rating difficulty. Scoring an information-only entry on dimensions designed for interventions is genuinely awkward. The choice was to score honestly low rather than to invent ways the entry "improves longevity" through some chain of indirect logic. The article's value is real but narrow, and the scores reflect that.
Voice call. The dek deliberately lands the punchline ("two things wearing the same name") before any nuance, because the reader walks in primed by whatever marketing they last saw. The misconceptions section is unusually direct — naming the commercial test failures by mechanism — because softening that material would dull the entry's whole point.
Leaky Gut
The biology underneath is well-studied. The "syndrome" sold around it has a flagship drug trial that just failed and tests that don't measure what they claim.
Skipping the months-long elimination diets and the supplement stack the marketing pushes saves your day-to-day life a small but real amount of friction.
Knowing this is a marketed term, not a hidden disease, lets you stop worrying about a diagnosis nobody can actually make.